Chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in esophageal cancer invading aorta or trachea : A phase 2 trail

Miyata Hiroshi0 个研究点目标入组 20 人开始时间: 2019年10月8日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1 The first occurrence of thoracic esophageal cancer for which diagnosis of squamous cell carcinoma (including adenosquamous cell carcinoma and basal cell carcinoma) was obtained by histology
•Example (including cases that partially affect the cervical esophagus or abdominal esophagus)
•2 Thoracic esophagus cancer (cT4 esophagus cancer) with clinical involvement of the aorta or trachea without curative organ metastasis.
•Abdominal lymph node (No. 1, 2, 3, 7, 9) metastasis-positive cases are eligible.
•3 over 20 years old and under 80 years old
•4 PS (ECOG) 0-1
•5 There is no prior treatment for esophageal cancer. However, endoscopic resection (pT1a, ly0, v0) obtained with curative resection is acceptable.
•6 No history of radiation exposure to neck and chest
•7 Main organ function is maintained
•8 Patients who have obtained consent from the patient

•1 Chemoradiotherapy is difficult to perform due to abnormalities in major organs (brain, heart, lung, liver, kidney)
•2 active double cancer
•(However, cases that can be cured by treatment are eligible)
•3 Perforation or penetration case by primary lesions or lymph nodes
•4 Cases with a history of serious drug hypersensitivity
•5 pregnant women, lactating women and women with the possibility and intention of pregnancy
•6 Cases with severe pulmonary emphysema or pulmonary fibrosis or interstitial pneumonia recognized by lung function test, CT
•7 HBs antigen positive cases
•8 Cases deemed inappropriate by the investigator

发起方

Miyata Hiroshi